ArticleTranslational pediatrics2025
Interleukin-6, serum albumin levels, and acute kidney injury jointly predict in-hospital mortality in pediatric COVID-19 patients.
Article in Translational pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Prognostic Value of Inflammatory Markers in Paediatric Acute Kidney Injury.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Severe coronavirus disease 2019 (COVID-19) is less common in children; nevertheless, it carries a mortality risk. Accurate prognostic tools for early risk stratification are therefore essential. This study evaluated the predictive capacity of a combination of interleukin-6 (IL-6), serum albumin (ALB), and acute kidney injury (AKI) for in-hospital mortality in this patient group. Methods: A multicenter retrospective cohort study was conducted on pediatric patients with COVID-19 Omicron variant infection hospitalized between December 2021 and January 2022. The patients were stratified into risk groups based on their IL-6 levels, ALB levels, and the presence of AKI. Logistic regression and Cox proportional hazard models were used to evaluate associations between these biomarkers and in-hospital mortality. Results: A total of 119 children (70 males, 49 females) with severe COVID-19 were included in this study. No AKI cases were observed in survivors, whereas 47.1% (8/17) of nonsurvivors had AKI, a statistically significant difference (P<0.001). Univariate logistic regression and multivariate Cox regression analyses identified IL-6, ALB, and creatinine as significant predictors of inpatient mortality [IL-6, hazard ratio (HR): 1.003, 95% confidence interval (CI): 1.001-1.004, P<0.001; ALB, HR: 0.839, 95% CI: 0.761-0.925, P<0.001; creatinine, HR: 1.010, 95% CI: 1.006-1.014, P<0.001]. Receiver operating characteristic (ROC) analysis confirmed IL-6 [cutoff: 83.4 pg/mL, area under the curve (AUC): 0.897, P<0.001] and creatinine (cutoff: 67.05 µmol/L, AUC: 0.885, P<0.001) as strong predictors of mortality. Kaplan-Meier survival analysis showed a significantly higher mortality rate in the high-risk group compared to the medium- and low-risk groups (P<0.001). Conclusions: The combined assessment of IL-6, ALB, and AKI effectively predicts inpatient mortality in pediatric COVID-19 patients, enabling early identification of high-risk cases and supporting stratified clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.